Diligence memo · auto-generated · as of July 2, 2026
Braeburn Pharmaceuticals, Inc.
Braeburn Pharmaceuticals, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Braeburn Pharmaceuticals, Inc. operates in Biotechnology, based in PRINCETON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Braeburn Pharmaceuticals, Inc. has raised $110M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $110M on 2018-01-08.
Most recent recorded round closed around 2018-01-08.
Valuation (modeled)modeled
Provath models Braeburn Pharmaceuticals, Inc. at approximately $4.5B (range $499M–$9.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.04× the median modeled value of Series D+ Biotechnology companies in 2016–2018 (13 peers) — value vs value, same stage and era. Within the normal band (104% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 8.5 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 91% of Biotechnology peers (4293 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Guardant Health, Inc., Humacyte, Inc., Atreca, Inc., Semma Therapeutics, Inc., Schrodinger, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.